Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $46 to $48.
February 29, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Crinetics Pharmaceuticals and raises the price target from $46 to $48.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100